243 related articles for article (PubMed ID: 31250955)
1. Ethynylphosphonamidates for the Rapid and Cysteine-Selective Generation of Efficacious Antibody-Drug Conjugates.
Kasper MA; Stengl A; Ochtrop P; Gerlach M; Stoschek T; Schumacher D; Helma J; Penkert M; Krause E; Leonhardt H; Hackenberger CPR
Angew Chem Int Ed Engl; 2019 Aug; 58(34):11631-11636. PubMed ID: 31250955
[TBL] [Abstract][Full Text] [Related]
2. Cysteine-Selective Phosphonamidate Electrophiles for Modular Protein Bioconjugations.
Kasper MA; Glanz M; Stengl A; Penkert M; Klenk S; Sauer T; Schumacher D; Helma J; Krause E; Cardoso MC; Leonhardt H; Hackenberger CPR
Angew Chem Int Ed Engl; 2019 Aug; 58(34):11625-11630. PubMed ID: 30828930
[TBL] [Abstract][Full Text] [Related]
3. Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs.
Behrens CR; Ha EH; Chinn LL; Bowers S; Probst G; Fitch-Bruhns M; Monteon J; Valdiosera A; Bermudez A; Liao-Chan S; Wong T; Melnick J; Theunissen JW; Flory MR; Houser D; Venstrom K; Levashova Z; Sauer P; Migone TS; van der Horst EH; Halcomb RL; Jackson DY
Mol Pharm; 2015 Nov; 12(11):3986-98. PubMed ID: 26393951
[TBL] [Abstract][Full Text] [Related]
4. High-Throughput Cysteine Scanning To Identify Stable Antibody Conjugation Sites for Maleimide- and Disulfide-Based Linkers.
Ohri R; Bhakta S; Fourie-O'Donohue A; Dela Cruz-Chuh J; Tsai SP; Cook R; Wei B; Ng C; Wong AW; Bos AB; Farahi F; Bhakta J; Pillow TH; Raab H; Vandlen R; Polakis P; Liu Y; Erickson H; Junutula JR; Kozak KR
Bioconjug Chem; 2018 Feb; 29(2):473-485. PubMed ID: 29425028
[TBL] [Abstract][Full Text] [Related]
5. Homogeneous antibody-drug conjugates: DAR 2 anti-HER2 obtained by conjugation on isolated light chain followed by mAb assembly.
Farràs M; Miret J; Camps M; Román R; Martínez Ó; Pujol X; Erb S; Ehkirch A; Cianferani S; Casablancas A; Cairó JJ
MAbs; 2020; 12(1):1702262. PubMed ID: 31876436
[TBL] [Abstract][Full Text] [Related]
6. Site-Specific Conjugation of Auristatins onto Engineered scFv Using Second Generation Maleimide to Target HER2-positive Breast Cancer in Vitro.
Aubrey N; Allard-Vannier E; Martin C; Bryden F; Letast S; Colas C; Lakhrif Z; Collinet N; Dimier-Poisson I; Chourpa I; Viaud-Massuard MC; Joubert N
Bioconjug Chem; 2018 Nov; 29(11):3516-3521. PubMed ID: 30352511
[TBL] [Abstract][Full Text] [Related]
7. Impact of cathepsin B-sensitive triggers and hydrophilic linkers on in vitro efficacy of novel site-specific antibody-drug conjugates.
Bryden F; Martin C; Letast S; Lles E; Viéitez-Villemin I; Rousseau A; Colas C; Brachet-Botineau M; Allard-Vannier E; Larbouret C; Viaud-Massuard MC; Joubert N
Org Biomol Chem; 2018 Mar; 16(11):1882-1889. PubMed ID: 29473076
[TBL] [Abstract][Full Text] [Related]
8. N-terminal selective conjugation method widens the therapeutic window of antibody-drug conjugates by improving tolerability and stability.
Ko MJ; Song D; Kim J; Kim JY; Eom J; Sung B; Son YG; Kim YM; Lee SH; You WK; Jung J
MAbs; 2021; 13(1):1914885. PubMed ID: 33904380
[TBL] [Abstract][Full Text] [Related]
9. Design, Synthesis, and in vitro Evaluation of Multivalent Drug Linkers for High-Drug-Load Antibody-Drug Conjugates.
Chen B; Gianolio DA; Stefano JE; Manning CM; Gregory RC; Busch MM; Brondyk WH; Miller RJ; Dhal PK
ChemMedChem; 2018 Apr; 13(8):790-794. PubMed ID: 29517131
[TBL] [Abstract][Full Text] [Related]
10. Development and evaluation of β-galactosidase-sensitive antibody-drug conjugates.
Kolodych S; Michel C; Delacroix S; Koniev O; Ehkirch A; Eberova J; Cianférani S; Renoux B; Krezel W; Poinot P; Muller CD; Papot S; Wagner A
Eur J Med Chem; 2017 Dec; 142():376-382. PubMed ID: 28818506
[TBL] [Abstract][Full Text] [Related]
11. Design and Validation of Linkers for Site-Specific Preparation of Antibody-Drug Conjugates Carrying Multiple Drug Copies Per Cysteine Conjugation Site.
Kumar A; Mao S; Dimasi N; Gao C
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32961794
[TBL] [Abstract][Full Text] [Related]
12. Efficient Preparation of Site-Specific Antibody-Drug Conjugates Using Cysteine Insertion.
Dimasi N; Fleming R; Zhong H; Bezabeh B; Kinneer K; Christie RJ; Fazenbaker C; Wu H; Gao C
Mol Pharm; 2017 May; 14(5):1501-1516. PubMed ID: 28245132
[TBL] [Abstract][Full Text] [Related]
13. Effect of Conjugation Site and Technique on the Stability and Pharmacokinetics of Antibody-Drug Conjugates.
Kaempffe A; Dickgiesser S; Rasche N; Paoletti A; Bertotti E; De Salve I; Sirtori FR; Kellner R; Könning D; Hecht S; Anderl J; Kolmar H; Schröter C
J Pharm Sci; 2021 Dec; 110(12):3776-3785. PubMed ID: 34363839
[TBL] [Abstract][Full Text] [Related]
14. Site-Specific Dual Antibody Conjugation via Engineered Cysteine and Selenocysteine Residues.
Li X; Patterson JT; Sarkar M; Pedzisa L; Kodadek T; Roush WR; Rader C
Bioconjug Chem; 2015 Nov; 26(11):2243-8. PubMed ID: 26161903
[TBL] [Abstract][Full Text] [Related]
15. Recent Chemical Approaches for Site-Specific Conjugation of Native Antibodies: Technologies toward Next-Generation Antibody-Drug Conjugates.
Yamada K; Ito Y
Chembiochem; 2019 Nov; 20(21):2729-2737. PubMed ID: 30973187
[TBL] [Abstract][Full Text] [Related]
16. Highly Potent, Anthracycline-based Antibody-Drug Conjugates Generated by Enzymatic, Site-specific Conjugation.
Stefan N; Gébleux R; Waldmeier L; Hell T; Escher M; Wolter FI; Grawunder U; Beerli RR
Mol Cancer Ther; 2017 May; 16(5):879-892. PubMed ID: 28258164
[TBL] [Abstract][Full Text] [Related]
17. Highly homogeneous antibody modification through optimisation of the synthesis and conjugation of functionalised dibromopyridazinediones.
Bahou C; Richards DA; Maruani A; Love EA; Javaid F; Caddick S; Baker JR; Chudasama V
Org Biomol Chem; 2018 Feb; 16(8):1359-1366. PubMed ID: 29405223
[TBL] [Abstract][Full Text] [Related]
18. Impact of Payload Hydrophobicity on the Stability of Antibody-Drug Conjugates.
Buecheler JW; Winzer M; Tonillo J; Weber C; Gieseler H
Mol Pharm; 2018 Jul; 15(7):2656-2664. PubMed ID: 29809017
[TBL] [Abstract][Full Text] [Related]
19. A Simple and Efficient Method to Generate Dual Site-Specific Conjugation ADCs with Cysteine Residue and an Unnatural Amino Acid.
Zhang L; Wang Z; Wang Z; Luo F; Guan M; Xu M; Li Y; Zhang Y; Wang Z; Wang W
Bioconjug Chem; 2021 Jun; 32(6):1094-1104. PubMed ID: 34013721
[TBL] [Abstract][Full Text] [Related]
20. One-Pot Conversion of Free Sialoglycans to Functionalized Glycan Oxazolines and Efficient Synthesis of Homogeneous Antibody-Drug Conjugates through Site-Specific Chemoenzymatic Glycan Remodeling.
Ou C; Li C; Zhang R; Yang Q; Zong G; Dai Y; Francis RL; Bournazos S; Ravetch JV; Wang LX
Bioconjug Chem; 2021 Aug; 32(8):1888-1897. PubMed ID: 34351736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
